Skip to content

Abstract B013: Interrogating and modeling progression of early pancreatic intraepithelial neoplasia

Sep 2026 · Cancer Research · 0 citations

TL;DR

To better understand how specific alterations to epithelial or microenvironmental cell states impact progression of human PanINs, researchers are analyzing the composition, organization, and cellular states of early human PanIN lesions and designing manipulable in vitro co-culture models that mimic early human lesions.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with one of the lowest five-year survival rates of all cancers. Low grade, premalignant pancreatic intraepithelial neoplasias (PanINs) are common in the general population, but despite expression of mutant KRAS, the vast majority of these lesions will never progress to cancer. Understanding how additional genetic or epigenetic changes as well as changes to the tumor microenvironment contribute to PanIN to PDAC progression is critical and has the potential to reveal mechanisms of interception for this deadly disease. To better understand how specific alterations to epithelial or microenvironmental cell states impact progression of human PanINs, we are (1) analyzing the composition, organization, and cellular states of early human PanIN lesions and (2) designing manipulable in vitro co-culture models that mimic early human lesions. To understand the cell types, cell states, and spatial organization of PanIN lesions, we have collected >25 organ donor pancreata from people without cancer diagnoses. We histologically assessed multiple regions from the head, body, and tail of each pancreas to select ROIs for further genomic, transcriptomic, and proteomic analysis. We performed spatial transcriptomics on 72 ROIs selected from 13 donors, representing distinct age, BMI, and other lifestyle characteristics. Ongoing spatial transcriptomic analysis is determining the cellular composition and pathway usage among epithelial, stromal, and immune cell types across these different lesions, and these will be compared to the cell type and state changes observed in later stage lesions and pancreatic cancer. In order to build in vitro models testing hypotheses derived from this analysis, we have also created epithelial organoid and fibroblast lines from many of the normal pancreata. Using these primary derived cell lines along with additional purchased primary or immortalized cell lines, we are generating complex 3D bioprinted co-culture models of early disease progression. We are comparing phenotypic, proteomic, and transcriptomic changes to the epithelial cells and the microenvironment following distinct combinations or genetic perturbations of the different cell types. These models will be used to interrogate and understand the crosstalk that can permit progression of pancreatic cancer and to identify and test targets to intercept this process. Tana Gazdik, Madeline Kuhn, Kyra Lindley, Aaron Doe, Brian Mau, Ellen M. Langer. Interrogating and modeling progression of early pancreatic intraepithelial neoplasia [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B013.

View source

Similar papers

Sep 2026

Abstract A090: Quantitative evaluation of changes to healthy pancreatic microanatomy across the human lifespan

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy, with a five-year survival rate near 10%. The rarity of PDAC contrasts the abundance of its primary precursor lesion, pancreatic intraepithelial neoplasia (PanIN). PanIN is known to be common in surgically resected pancreas and to exist even in normal don...

Valentina Matos-Romero, Kara A. Lombardo, Daniela Higuera-Garrido et al. · 0 citations
Sep 2026

Abstract A080: Spatial transcriptomic analysis reveals obesity driven upregulation of inflammatory markers and matrix remodeling in healthy donor pancreas

Pancreatic Ductal Adenocarcinoma (PDAC) is a lethal disease with a 5-year survival rate of 13%. This low survival rate is due in part to insufficient knowledge surrounding pre-cancerous lesions and lack of early detection methods, leading to late-stage diagnoses and inadequate treatment options. Understanding the mec...

T. Gazdik, Madeline R. Kuhn, A. Doe et al. · 0 citations
Sep 2026

Abstract A034: Spatial multi-omics defines cancer-like precursor lesions in human pancreas

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive type of pancreatic cancer classically driven by oncogenic KRAS mutations. It is thought to arise from precursor lesions including intraductal papillary mucinous neoplasia (IPMN) and pancreatic intraepithelial neoplasia (PanIN). We have recently reported that Pa...

J. Okoye, Rosina Carr, Carlos E. Espinoza et al. · 0 citations
Sep 2026

Abstract B087: Impact of RAS inhibition on T cell maturation in the PDAC microenvironment

It is suggested that pharmacologic and genetic KRAS inhibition differentially remodel the intratumoral T cell compartment, whereas both induce similar T cell changes within the liver premetastatic niche.

Lauren Gerbereux, Rashmi Kumar, E. Lasse-Opsahl et al. · 0 citations
Sep 2026

Abstract IA007: Getting ahead of the tumor: Interception approaches for pancreas cancer

Pancreatic ductal adenocarcinoma (PDAC) emerges from precursor lesions (PanINs and IPMNs) that harbor mutations in the KRAS oncogene. Once thought to be untargetable, the KRAS oncoprotein can now be inhibited with small molecule compounds that bind to either the active or inactive form of the protein. KRAS inhibitors...

Ben Z. Stanger, Minh T. Than, Lucie Dequiedt et al. · 0 citations
Sep 2026

Abstract A053: Defining THOC3 as a key dependency in basal-squamous pancreas cancer subtype specification and growth

Pancreas cancer is an extremely deadly malignancy expected to become the second leading cause of cancer-related deaths by 2030. While pancreatic ductal adenocarcinoma (PDAC) has been the main focus of the field, subclones of different subtypes of disease, including basal-squamous, are admixed in tumors. The basal-squ...

Hannah N. Pettit, Jennifer C. Lee, Mathew T. Chvasta et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.